NDC 63285-0800-00: ivosidenib 250 mg Tablet, Film Coated, Drum of 11,429
This is a package of 11,429 tablets of ivosidenib 250 mg Tablet, Film Coated from Patheon Inc., first listed with the FDA Jul 2018 and currently FDA-listed. It is this product's only package size.
NDC database record
One package, one record: these facts belong to NDC 63285-800-00 alone.
- Record
- FDA NDC Directory package listing · Drug for further processing
- Code segments
- 63285 labeler · 800 product · 00 package
- Package marketed since
- Jul 20, 2018
- Listing certified through
- Dec 31, 2027
- Barcode (UPC-A, from the NDC)
- 3 6328580000 1
- FDA record last changed
- Oct 22, 2026
Identity & classification
Regulatory identifiers FDA, NLM and CMS codes for this package
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- FDA label on DailyMed · label index refreshed Nov 21, 2026
- RxNorm (NLM RxNav) · catalog refreshed Nov 19, 2026
- Medi-Span GPI (licensed)
- First Databank (licensed) · refreshed Nov 19, 2026
Clinical
- It treats certain adults with AML, MDS, or previously treated bile duct cancer (cholangiocarcinoma) whose cancer has an IDH1 mutation. A test will confirm this before you start.
- Take it as soon as you remember, as long as it is at least 12 hours before your next dose. Then go back to your normal schedule the next day. Never take 2 doses within 12 hours, an...
- What happens if I miss a dose of ivosidenib?
- Yes, with or without food. Just avoid a high-fat meal, because it makes your body absorb more of the drug. Swallow the tablet whole.
Patient education
Drug interactions
Supplement & herbal interactions
Some supplements/herbs that may interact with Ivosidenib — tap one for details:
Where does this data come from?
- MedlinePlus (NLM) · refreshed Nov 19, 2026
- FDA label on DailyMed · label index refreshed Nov 21, 2026
Ask a licensed pharmacist directly — free, answered by our team.
Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per each | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | Not in the retail survey — common for institutional, discontinued, or low-volume packs. | |
| Medicaid paysCMS SDUD · 12 mo | No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data. | |
| Medicare drug plans payPart D · quarterly | No Part D plan price is available for this NDC in our data. | |
Where does this data come from?
- CMS NADAC weekly file
- CMS ASP pricing files · refreshed Nov 20, 2026
- CMS Medicaid State Drug Utilization Data · refreshed Nov 19, 2026
- CMS Part D plan pricing files · refreshed Oct 24, 2026
- VA National Acquisition Center price file
Packaging — all sizes for this product
| Package NDC | Description | Marketing start | Marketing end | Status |
|---|---|---|---|---|
| 63285-0800-00 You're viewing this Main listing | 11429 TABLET, FILM COATED in 1 DRUM | — | — | Active |
Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| ivosidenib 250 mgthis 63285-0800-00 | Patheon | 11429 tablets | — | — | FDA listed | — |
| Tibsovo 250 mg 72694-0617-60 | Servier | 60 tablets | — | — | FDA listed | — |
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- FDA Orange Book · refreshed Nov 6, 2026
- CMS NADAC weekly file
Availability & generic status
We did not find an FDA-approved generic match for this exact strength, form and route.
Where does this data come from?
- FDA Orange Book · refreshed Nov 6, 2026
Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
🧪 Avoiding an ingredient? See Ivosidenib inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.
Where does this data come from?
IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.- FDA label on DailyMed · label index refreshed Nov 21, 2026
- FDA openFDA NDC Directory · synced Nov 19, 2026
Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
Manufacturer & labeler
More NDCs from Patheon Inc. labeler code 63285
- lenvatinib 10 mg Capsule NDC 63285-757-00
- lenvatinib 4 mg Capsule NDC 63285-758-00
- elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide fumarate 150 mg; 150 mg; 200 mg; 10 mg Tablet NDC 63285-763-00
- emtricitabine and tenofovir alafenamide fumarate 200 mg; 25 mg Tablet NDC 63285-772-00
- Tenofovir Alafenamide Fumarate 25 mg Tablet NDC 63285-797-00
- velpatasvir and sofosbuvir 100 mg; 400 mg Tablet, Film Coated NDC 63285-799-00
- Darunavir, Cobicistat, Emtricitabine, and Tenofovir alafenamide 800 mg; 150 mg; 200 mg; 10 mg Tablet, Film Coated NDC 63285-816-00
- armodafinil 200 mg Tablet NDC 63285-827-01
- Rolapitant Hydrochloride 90 mg Tablet NDC 63285-828-00
- eszopiclone 1 mg Tablet, Coated NDC 63285-830-00
- eszopiclone 2 mg Tablet, Coated NDC 63285-831-00
- eszopiclone 3 mg Tablet, Coated NDC 63285-832-00
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- Drugs@FDA
Full FDA label FDA SPL
📄 FDA label ▾
No FDA label is on file for this product yet. Labels load from openFDA / DailyMed and refresh weekly.
Medicare Part D spend CMS · PART D · 2026 (Q1)
Reported adverse events (FAERS)
Top reported reactions
Age at onset
Reporter sex
Serious outcomes
Where does this data come from?
About this NDC listing & data coverage
What "drug for further processing" means
FDA lists this package under the "drug for further processing" marketing category: Patheon Inc. supplies it to other companies for further processing or repackaging (blister cards that are later repackaged or co-packaged are a common example). The units themselves are a finished dosage form — which is why pricing or Medicaid data can still appear — but this exact package code may not be the presentation a retail pharmacy dispenses.
What data is (and isn’t) available for this NDC — tap to expand
| NDC identity (package / product / labeler codes) | ✓ Available |
| Labeler | ✓ Available |
| Product & package description | ✓ Available |
| Marketing category & status | ✓ Available |
| Active ingredient / dosage form / route | ✓ Available |
| FDA label (SPL via DailyMed) | ✓ Available |
| Package photos | — Not published for this NDC No photo available yet for this listing. |
| Inactive ingredients (structured) | — Not published for this NDC The labeler did not submit a structured excipient list, or no SPL is available. |
| NADAC pharmacy acquisition price (CMS) | — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey. |
| Orange Book / therapeutic-equivalence data | — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope. |
| HCPCS J-code billing crosswalk | — Not published for this NDC Most self-administered / retail products have no J-code — that is normal. |
| Medicaid utilization (CMS SDUD) | — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold. |